As of 2026-09-14, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -2.63. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 303.78 mil USD. KPTI's TTM EBITDA according to its financial statements is -115.33 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.0x - 15.9x | 13.0x |
| Forward P/E multiples | 12.2x - 18.3x | 16.6x |
| Fair Price | (74.09) - (92.82) | (87.12) |
| Upside | -4701.9% - -5865.2% | -5511.2% |
| Date | EV/EBITDA |
| 2026-09-08 | -2.66 |
| 2026-09-04 | -2.67 |
| 2026-09-03 | -2.67 |
| 2026-09-02 | -2.67 |
| 2026-09-01 | -2.68 |
| 2026-08-31 | -2.72 |
| 2026-08-28 | -2.69 |
| 2026-08-27 | -2.70 |
| 2026-08-26 | -2.70 |
| 2026-08-25 | -2.69 |
| 2026-08-24 | -2.68 |
| 2026-08-21 | -2.70 |
| 2026-08-20 | -2.68 |
| 2026-08-19 | -2.71 |
| 2026-08-18 | -2.70 |
| 2026-08-17 | -2.67 |
| 2026-08-14 | -2.71 |
| 2026-08-13 | -2.71 |
| 2026-08-12 | -2.72 |
| 2026-08-11 | -2.73 |
| 2026-08-10 | -2.70 |
| 2026-08-07 | -2.73 |
| 2026-08-06 | -2.70 |
| 2026-08-05 | -2.69 |
| 2026-08-04 | -2.70 |
| 2026-08-03 | -2.70 |
| 2026-07-31 | -2.69 |
| 2026-07-30 | -3.70 |
| 2026-07-29 | -3.67 |
| 2026-07-28 | -3.71 |
| 2026-07-27 | -3.71 |
| 2026-07-24 | -3.77 |
| 2026-07-23 | -3.71 |
| 2026-07-22 | -3.73 |
| 2026-07-21 | -3.86 |
| 2026-07-20 | -3.79 |
| 2026-07-17 | -4.19 |
| 2026-07-16 | -4.16 |
| 2026-07-15 | -4.19 |
| 2026-07-14 | -4.28 |
| 2026-07-13 | -4.29 |
| 2026-07-10 | -4.35 |
| 2026-07-09 | -4.32 |
| 2026-07-08 | -4.41 |
| 2026-07-07 | -4.29 |
| 2026-07-06 | -4.21 |
| 2026-07-02 | -4.20 |
| 2026-07-01 | -4.19 |
| 2026-06-30 | -4.24 |
| 2026-06-29 | -4.30 |